The drug inhibits the growth of tumors, exerts influence on a number of biochemical indices: monoaminooksidaznuyu activity inhibits, reduces the permeability of cell membranes and subcellular structures, biological membranes, is an inhibitor of the metabolism of xenobiotics. It has a therapeutic effect in symptomatic malignant tumors in advanced stages. It does not have mielodepressivnymi and other side effects typical of many other anticancer drugs.
The content of the drug in the blood of human patients reaching a peak after 2 hours after taking 60 mg (1 tablet); a day in the serum also determined by its small amounts. When selecting the blood after 9 hours after 30-day course of treatment among patients detected from 0 to 89 ng / ml Segidrina®.
A study of the pharmacokinetics Segidrina® was also performed on mongrel intact rats and animals with sarcoma 45. The drug is rapidly absorbed from the gastrointestinal tract; purification from blood it ends at the 25-28 th hour after intragastric administration in a dose of 100 mg / kg.
Maximum blood concentration of intact animals begins about 50 minutes after administration, at the tumor (sarcoma 45) – after 3 h.
Registered increased 3-5 fold accumulation of substances in the liver, kidney and lung in comparison with blood, but not in the tumor; purification of intact organs of healthy animals with tumors and ends by the end of the 4th day. Urinary excretion in healthy animals continues to 3 days and is approximately 50% of the initial amount; in tumor elimination ends between the first and second days, and displayed only 25% of the formulation. Volume of distribution, in intact rats is 14 ml, the presence of tumor – 29.4 ml. Tumor prone to accumulation SEHYDRIN. Segidrin® oxidized in the body, and its part undefeated excreted in the urine, partly acetylated form (rats and rabbits).
Pharmsintez PJSC, Russia
1 tablet contains:
hydrazine sulfate 60 mg.
calcium phosphate dibasic,
polyethylene glycol 600,
iron oxide red (E172),
The blister 10 tablets. In multiples of 5 blisters.
- Symptomatic treatment of locally advanced and disseminated forms of malignancies.
Thus the preparation has a pronounced Segidrin® symptomatic effect: the reduction or elimination of pain (up to discontinuing the drug), feeling of weakness, respiratory failure phenomena (dyspnea), cough, fever, improved appetite, increased motor activity. The drug is administered to patients with malignant tumors in advanced stages (including preterminal phase process).
- Increased sensitivity to hydrazine sulfate and other components of the drug;
- the simultaneous use of all types of alcohol and barbiturates;
- Pregnancy and lactation;
- children’s age (due to the lack of application experience).
Precautions: when expressed by human liver and kidneys.
Possible dyspeptic effects (nausea, vomiting, belching), passing rapidly at lower doses or intermittent (two-, three-day) break in treatment. Rare complications – insomnia, general excitement, not pronounced and transient phenomena of polyneuritis.
When administered dyspeptic phenomena inside astringent and anti-inflammatory agents (camomile, romazulan, Vicalinum), antiemetics and spasmolytics. By appropriate use of the neurotoxic effects of pyridoxine hydrochloride (5% Vitamin B6 1 ml solution by intramuscular injection 1-2 times per day), thiamine chloride (vitamin B1), multivitamin preparations and intravenous inwardly 20-40% dextrose (glucose).
How to accept, acceptance rate and dosage
Segidrin® prescribed orally for 1-2 hours or up to 1-2 hours after eating or taking other medications. Adults are preparation of 1 tablet 3 times daily. Heading dose – 100 tablets. When poor tolerability daily dose is reduced to 2 tablets per day. Dose course of treatment at the same time can not be changed.
Repeated treatment is carried out at intervals of not less than 14 days. The number of courses is not limited to, the intervals between courses increased by 1-2 weeks.
In a dry place, protected from light at a temperature not higher than 25 ° C
Simultaneous reception SEHYDRIN with barbiturates, ethanol, tranquilizers, antipsychotic drugs (neuroleptics) can lead to a sharp increase SEHYDRIN toxicity.
In experiments on laboratory animals in the case of previous reception SEHYDRIN effective treatment of many antineoplastic agents is increased (exception – cyclophosphamide).
SEHYDRIN Treatment should be under the supervision of a physician who is experienced in the use of anticancer drugs.
The drug is administered with caution to patients with functional disorders of the liver and kidneys. Use of the drug in jaundice induced liver metastases (particularly obstructive) contraindicated.
It is necessary to exclude the use of ethanol-containing beverages as well as foods rich in tyramine: cheese, raisins, canned foods, sausages, yogurts.
Given the lack of myelotoxicity Segidrin® used for patients with cytopenia resulting from radiation therapy and chemotherapy.
Pregnancy and lactation
Contraindicated during pregnancy and lactation.